Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Clinics ; 69(10): 666-671, 10/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-730466

RESUMEN

OBJECTIVES: Cardiology referral is common for patients admitted for non-cardiac diseases. Recommendations from cardiologists may involve complex and aggressive treatments that could be ignored or denied by other physicians. The purpose of this study was to compare the outcomes of patients who were given recommendations during cardiology referrals and to examine the clinical outcomes of patients who did not follow the recommendations. METHODS: We enrolled 589 consecutive patients who received in-hospital cardiology consultations. Data on recommendations, implementation of suggestions and outcomes were collected. RESULTS: Regarding adherence of the referring service to the recommendations, 77% of patients were classified in the adherence group and 23% were classified in the non-adherence group. Membership in the non-adherence group (p<0.001; odds ratio: 10.25; 95% CI: 4.45-23.62) and advanced age (p = 0.017; OR: 1.04; 95% CI: 1.01-1.07) were associated with unfavorable outcomes. Multivariate analysis identified four independent predictors of adherence to recommendations: follow-up notes in the medical chart (p<0.001; OR: 2.43; 95% CI: 1.48-4.01); verbal reinforcement (p = 0.001; OR: 1.86; 95% CI: 1.23-2.81); a small number of recommendation (p = 0.001; OR: 0.87; 95% CI: 0.80-0.94); and a younger patient age (p = 0.002; OR: 0.98; 95% CI: 0.96-0.99). CONCLUSIONS: Poor adherence to cardiology referral recommendations was associated with unfavorable clinical outcomes. Follow-up notes in the medical chart, verbal reinforcement, a limited number of recommendations and a patient age were associated with greater adherence to recommendations. .


Asunto(s)
Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Cardiología/normas , Adhesión a Directriz/estadística & datos numéricos , Derivación y Consulta/estadística & datos numéricos , Factores de Edad , Hospitales Universitarios/estadística & datos numéricos , Unidades de Cuidados Intensivos , Modelos Logísticos , Oportunidad Relativa , Estudios Prospectivos , Encuestas y Cuestionarios , Resultado del Tratamiento
2.
Arq. bras. cardiol ; 85(supl.5): 58-61, out. 2005. graf
Artículo en Portugués | LILACS | ID: lil-418878

RESUMEN

Dislipidemias podem ser observadas precocemente entre pacientes com AIDS. Frequentemente, estas anormalidades lipídicas incluem HDL baixo e moderado aumento dos triglicérides sanguíneos. A terapia anti-retroviral combinada (HAART) pode agravar a dislipidemia nestes pacientes, com importante aumento nos triglicérides e no LDL. Vários mecanismos são propostos para explicar a dislipidemia mista observada nestes indivíduos, incluindo diferentes etapas do metabolismo lipídico. A importância do tratamento desses distúrbios lipídicos tem se tornado evidente com o aumento da expectativa de vida e os relatos de complicações cardiovasculares nestes pacientes. Existe um estado de resistência à insulina nos pacientes com AIDS em tratamento com HAART,que apresentam lipodistrofia, hipertrigliceridemia e baixos níveis de HDL. Drogas retro-antivirais são metabolizadas pelo CYP P450 3A4 e interações com algumas estatinas, especialmente com sinvastatina podem ocorrer. O tratamento com agentes hipolipemiantes deve ser baseado no perfil lipídico e no risco de coronariopatia. Para hipertrigliceridemias, fibratos (principalmente fenofibrato ou bezafibrato) devem ser as drogas de escolha, bem como as estatinas (principalmente pravastatina). Terapia combinada usando estatinas mais fibratos é recomendada para dislipidemias mistas graves e sempre sob rigoroso monitoramento de efeitos adversos.


Asunto(s)
Humanos , Terapia Antirretroviral Altamente Activa , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Enfermedad de la Arteria Coronaria/etiología , Interacciones Farmacológicas , Dislipidemias/etiología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Metabolismo de los Lípidos/efectos de los fármacos , Síndrome de Inmunodeficiencia Adquirida/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA